RICHMOND, Calif., Sept. 30, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in therapeutic genome editing, announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president of corporate communications, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30pm PT on Wednesday, October 7, 2015, at the 2015 Stem Cell Meeting on the Mesa. In addition, as the Chairman of the Alliance for Regenerative Medicine (ARM), Edward Lanphier, Sangamo's president and chief executive officer, will open the meeting with a welcome address. The meeting will be held from October 7-9 in La Jolla, California.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The webcast will be archived on the Sangamo website and will also be published on the ARM website shortly after the event.
Co-hosted by ARM, the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring a two-day Partnering Forum, Public Forum lecture and a full-day Scientific Symposium.
This meeting is the cell and gene therapy sector's premiere forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.
At the Partnering Forum, held October 7 and 8, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today.
Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at email@example.com and interested media should contact Lyndsey Scull at firstname.lastname@example.org.
About Sangamo Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™ for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for Huntington's disease, and with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.